Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization

Roflumilast is currently administered orally to control acute exacerbations in chronic obstructive pulmonary disease (COPD). However, side effects such as gastrointestinal disturbance and weight loss have limited its application. This work aimed to develop an inhalable roflumilast formulation to red...

Descripción completa

Detalles Bibliográficos
Autores principales: Momin, Mohammad A. M., Adhikari, Bishal Raj, Sinha, Shubhra, Larson, Ian, Das, Shyamal C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400286/
https://www.ncbi.nlm.nih.gov/pubmed/34452215
http://dx.doi.org/10.3390/pharmaceutics13081254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400286/
https://www.ncbi.nlm.nih.gov/pubmed/34452215
http://dx.doi.org/10.3390/pharmaceutics13081254

Ejemplares similares